CCX 872

Drug Profile

CCX 872

Alternative Names: CCX 872 B; CCX-872

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action CCR1 receptor modulators; CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Cancer; Non-alcoholic steatohepatitis
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 22 Jan 2018 Updated efficacy data from a phase Ib trial in Pancreatic cancer released by ChemoCentryx
  • 02 Aug 2017 Phase I development is ongoing in Netherlands (NCT02345408)
  • 02 Aug 2017 Discontinued - Preclinical for Diabetic nephropathies in USA (PO) (ChemoCentryx pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top